<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biosci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Biosci. Rep</journal-id><journal-id journal-id-type="hwp">ppbioscirep</journal-id><journal-id journal-id-type="publisher-id">BSR</journal-id><journal-title-group><journal-title>Bioscience Reports</journal-title></journal-title-group><issn pub-type="ppub">0144-8463</issn><issn pub-type="epub">1573-4935</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28356484</article-id><article-id pub-id-type="pmc">5529204</article-id><article-id pub-id-type="doi">10.1042/BSR20170020</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>25</subject><subject>39</subject><subject>31</subject></subj-group></article-categories><title-group><article-title>A randomized placebo-controlled clinical study of <italic>nab</italic>-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Wu</surname><given-names>Yueming</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="corresp" rid="COR1"/></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Jiang</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Weiwei</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Qingquan</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><aff id="A1"><label>1</label>Department of Thoracic Surgery, The People&#x02019;s Hospital of Dongyang City, 60 Wuning West Road, Dongyang City, Zhejiang Province 322100, China</aff><aff id="A2"><label>2</label>Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai JiaoTong Universty, Shanghai 200030, China</aff></contrib-group><author-notes><corresp id="COR1"><bold>Correspondence:</bold> Yueming Wu (<email>julyaris244@yeah.net</email>)</corresp></author-notes><pub-date pub-type="epreprint"><day>29</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>27</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><day>31</day><month>8</month><year>2017</year></pub-date><volume>37</volume><issue>4</issue><elocation-id>BSR20170020</elocation-id><history><date date-type="received"><day>09</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>23</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Author(s).</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="bsr-37-bsr20170020.pdf"/><abstract><p>We performed a randomized and placebo-controlled clinical study to investigate whether <italic>nab</italic>-paclitaxel can improve survival in patients with advanced non-small cell lung cancer (NSCLC) after unsuccessful first-line chemotherapy. Patients with stages III to IV advanced NSCLC after first-line platinum-based chemotherapy failure were randomly assigned in a 1:1 ratio to receive second-line treatment of <italic>nab</italic>-paclitaxel or placebo. Ninety two eligible patients were enrolled in the study. The median progression-free survival (PFS) was 4.6 months (95% confidence interval (CI): 3.4&#x02013;6.7 months) for <italic>nab</italic>-paclitaxel, compared with 2.0 months (95% CI: 0.9&#x02013;4.3 months) for placebo, representing a 56% reduction in disease progression (hazard ratio: 0.62; 95% CI: 0.33&#x02013;0.81; <italic>P</italic>&#x0003c;0.001). The median overall survival (OS) was 6.3 months (95% CI: 3.9&#x02013;8.2 months) for <italic>nab</italic>-paclitaxel, compared with 4.9 months (95% CI: 2.1&#x02013;5.9 months) for placebo, representing a 22% reduction in disease progression (hazard ratio: 0.71; 95% CI: 0.33&#x02013;0.85; <italic>P</italic>&#x0003c;0.001). Adverse events (AEs) were also observed for <italic>nab</italic>-paclitaxel. <italic>Nab</italic>-paclitaxel can improve survival in patients with advanced NSCLC after unsuccessful first-line chemotherapy.</p></abstract><kwd-group><kwd>NSCLC</kwd><kwd>nab-paclitaxel</kwd><kwd>OS</kwd><kwd>PFS</kwd><kwd>second-line</kwd></kwd-group><counts><page-count count="6"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer deaths in China and worldwide [<xref rid="B1" ref-type="bibr">1</xref>]. An estimated 1.8 million new lung cancer cases occurred in 2012, accounting for approximately 13% of total cancer diagnoses [<xref rid="B2" ref-type="bibr">2</xref>]. More than 80% of the lung cancer cases are non-small cell lung cancer (NSCLC) [<xref rid="B3" ref-type="bibr">3</xref>]. Although the 5-year survival rate for patients with localized NSCLC is more than 50%, approximately 57% patients have advanced/metastatic NSCLC at the time of diagnosis with only 5% survival rate [<xref rid="B4" ref-type="bibr">4</xref>]. The standard first-line therapy for advanced NSCLC without targetable genetic alterations is a platinum-based doublet including third-generation cytotoxic agents (e.g. cisplatin plus gemcitabine or carboplatin plus paclitaxel) [<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>]. Several single chemotherapy regimens, including docetaxel, pemetrexed, erlotinib and gefitinib, have been recommended as the second-line chemotherapy for patients with advanced NSCLC progressing after the first-line treatment [<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>]. However, there is still no standard guideline for the second-line chemotherapy.</p><p>The albumin-bound nanoparticle formulation of paclitaxel (<italic>nab</italic>-paclitaxel) is a solvent-free option for chemotherapy. <italic>Nab</italic>-paclitaxel combined with carboplatin has been approved by FDA for the first-line treatment of advanced NSCLC regardless of histologic subtypes in 2012 [<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>]. A phase III trial demonstrated that <italic>nab</italic>-paclitaxel plus carboplatin significantly improved overall response rates compared with conventional, solvent-based paclitaxel plus carboplatin in patients with advanced NSCLC [<xref rid="B11" ref-type="bibr">11</xref>]. Recently, increasing evidence suggested that <italic>nab</italic>-paclitaxel, either as a single chemotherapy reagent or in combination with gemcitabine, can be used as the second-line therapy for improving patients&#x02019; survival rates in pancreatic cancer [<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>] or gastric cancer [<xref rid="B14" ref-type="bibr">14</xref>]. However, there is still insufficient evidence to prove whether <italic>nab</italic>-paclitaxel is effective in the second-line chemotherapy for patients with advanced NSCLC. Therefore, we evaluated the efficacy and safety of single reagent <italic>nab</italic>-paclitaxel as the second-line treatment for patients who have advanced in this randomized placebo-controlled phase II clinical study in China.</p></sec><sec sec-type="materials|methods" id="sec2"><title>Materials and methods</title><sec id="sec2-1"><title>Ethics statement</title><p>All protocols in the present study were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. All procedures and treatments were reviewed and approved by the Ethics Committees at the People&#x02019;s Hospital of Dongyang city. All participating patients signed the consent forms.</p></sec><sec id="sec2-2"><title>Patients</title><p>Between October 2011 and October 2014, there were 92 eligible patients with advanced NSCLC participating in the present study at the People&#x02019;s Hospital of Dongyang city in Dongyang, Zhejiang province, China. Patients with advanced NSCLC were randomly stratified (in 1:1 ratio) into two treatment groups, placebo-controlled group (46 patients) and the nab-paclitaxel group (46 patients). Patients were included in the study if they were between 18 and 75 years, had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) between 0 and 3, had advanced (stage III/IV) NSCLC, had first-line platinum-based chemotherapy but still had progressing disease, had a life expectancy no shorter than 3 months and had adequate hepatic, renal or bone marrow functions. Patients were excluded if they were pregnant, had the radiation therapy within 1 week before enrollment, had the first-line chemotherapy within 3 weeks before enrollment, had major surgery within 6 months before enrollment or had other incurable diseases or tumours.</p></sec><sec id="sec2-3"><title>Study design and treatment</title><p>This is an open-label, placebo-controlled, randomized phase II clinical study that evaluates the efficacy and safety of <italic>nab</italic>-paclitaxel as second-line chemotherapy for Chinese patients with advanced NSCLC after the platinum-based first-line chemotherapy failure.</p><p>Computed tomographic scans of the chest and abdomen were obtained 2 weeks before the study. At least one measurable lesion was required for patients to be evaluated for a response.</p><p>For drug administration, patients in the <italic>nab</italic>-paclitaxel group were intravenously administrated with 150 mg/m<sup>2</sup> of <italic>nab</italic>-paclitaxel on days 1, 8 and 15 of a 4-week cycle. Patients should receive at least two cycles of treatment until failure to tolerate the adverse events (AEs) or request to discontinue the treatment with an upper limit of six cycles. Matched placebo was given to the patients in the control group.</p><p>Toxicities or AEs were estimated based on the guidelines of National Cancer Institute&#x02019;s Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0). Supportive treatment for tumour-related AEs was available for all patients. If grade 3 or 4 AEs were observed, <italic>nab</italic>-paclitaxel dose was reduced to 100 mg/m<sup>2</sup> and patients were provided with 4 mg dexamethasone plus 1 mg vitamin B<sub>12</sub> to reduce toxicities.</p></sec><sec id="sec2-4"><title>Statistical analysis</title><p>The primary endpoint in the present study was response rates (RRs). The secondary endpoints were overall survival (OS), progression-free survival (PFS) or AEs. OS and PFS were estimated by the Kaplan&#x02013;Meier model. The comparisons of PFS and OS were conducted with a considered log-rank test with a confidence interval (CI) of 95%.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3-1"><title>Patients</title><p>From October 2011 to October 2014, a total of 92 patients with advanced NSCLC were eligible for the study. They were randomly assigned to placebo-controlled group (<italic>n</italic>=46) and <italic>nab</italic>-paclitaxel group (<italic>n</italic>=46) in a 1:1 ratio. As shown in <xref ref-type="table" rid="T1">Table 1</xref>, the percentages of male/female patients in placebo-controlled group and <italic>nab</italic>-paclitaxel group were 56.5%/43.5% and 52.2%/47.8% respectively. The average ages were 57.2 years (25&#x02013;73 years) in placebo-controlled group and 58.5 years (23&#x02013;74 years) in <italic>nab</italic>-paclitaxel group respectively. In both the groups, more than 90% of patients had ECOG PS between 0 and 2, more than 90% patients were current or former smokers and approximately 70% of the patients had adenocarcinoma. After first-line platinum-based chemotherapy, the percentages of patients showing responses in placebo-controlled group and <italic>nab</italic>-paclitaxel group were 32.6 and 30.4% respectively. Also, the percentages of patients with stable diseases in placebo-controlled group and <italic>nab</italic>-paclitaxel group were 50.0 and 54.3% respectively. There were no significant differences in the clinical characteristics and baseline demographics suggesting that the patients&#x02019; baseline characteristics were well balanced between the two groups.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>The clinical characteristics and baseline demographics of Chinese patients with advanced NSCLC</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Category</th><th align="center" colspan="2" rowspan="1">Placebo (<italic>n</italic>=46)</th><th align="center" colspan="2" rowspan="1"><italic>Nab</italic>-paclitaxel (<italic>n</italic>=46)</th><th align="left" rowspan="1" colspan="1"><italic>P-</italic>value</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Sex, male/female</td><td align="center" rowspan="1" colspan="1">26/20</td><td align="center" rowspan="1" colspan="1">56.5/43.5</td><td align="center" rowspan="1" colspan="1">24/22</td><td align="center" rowspan="1" colspan="1">52.2/47.8</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1">Age, years (range)</td><td align="center" colspan="2" rowspan="1">57.2 (25&#x02013;73)</td><td align="center" colspan="2" rowspan="1">58.5 (23&#x02013;74)</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>ECOG PS</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">0&#x02013;1</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">67.4</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">63.0</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">28.3</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">37.0</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Lung cancer subtype</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">69.6</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">78.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1">Squamous-cell carcinoma</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">23.9</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">17.4</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.3</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Smoking history</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Present and former</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">93.5</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">91.3</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1">Never</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">8.7</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Response to first-line chemotherapy</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Complete + partial response</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">32.6</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">30.4</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1">Stable disease</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">50.0</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">54.3</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" rowspan="1" colspan="1">Progressive disease</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">17.4</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">15.2</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec><sec id="sec3-2"><title>Efficacy</title><p>The cut-off date of the present study was October 4th 2014 and the duration of treatment was approximately 2&#x02013;6 months. The RRs for patients in placebo-controlled group and <italic>nab</italic>-paclitaxel group are summarized in <xref ref-type="table" rid="T2">Table 2</xref>. The complete RRs were low in both groups, estimated as 0.0% (0/46) in placebo-controlled group and 2.2% (1/46) in <italic>nab</italic>-paclitaxel group. Encouragingly, the partial RR was much better in <italic>nab</italic>-paclitaxel group (17.4%, 8/46) than that in placebo-controlled group (4.3%, 2/46) (<italic>P</italic>&#x0003c;0.001). Thus, the objective RR was significantly improved, from 4.3 (2/46) in placebo-controlled group to 19.6% (9/46) in <italic>nab</italic>-paclitaxel group (<italic>P</italic>&#x0003c;0.001). Furthermore, the stable disease was also significantly improved, from 15.2 (7/46) in placebo-controlled group to 52.2% (24/46) in <italic>nab</italic>-paclitaxel group (<italic>P</italic>&#x0003c;0.001). The confirmed progressive disease rates were 67.4 (31/46) in placebo-controlled group and 43.5% (20/46) in <italic>nab</italic>-paclitaxel group.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Efficacy of Chinese patients with advanced NSCLC</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Placebo (<italic>n</italic>=46)</th><th align="center" colspan="2" rowspan="1">Nab-paclitaxel (<italic>n</italic>=46)</th></tr><tr><th align="left" rowspan="1" colspan="1"><bold>Responses</bold></th><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Complete response</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Partial response</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.3</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">17.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Objective response</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.3</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">19.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Stable disease</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">10.9</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">32.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Disease control rate</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">15.2</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">52.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Progressive disease</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">67.4</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">43.5</td></tr></tbody></table></table-wrap><p>The median PFS and OS were compared between the two groups (<xref ref-type="fig" rid="F1">Figure 1</xref>). The PFS was 4.6 months (95% CI: 3.4&#x02013;6.7 months) for <italic>nab</italic>-paclitaxel, compared with 2.0 months (95% CI: 0.9&#x02013;4.3 months) for placebo, representing a 56% reduction in disease progression (hazard ratio: 0.62; 95% CI: 0.33-0.81; <italic>P</italic>&#x0003c;0.001). The median OS was 6.3 months (95% CI: 3.9-8.2 months) for <italic>nab</italic>-paclitaxel, compared with 4.9 months (95% CI: 2.1&#x02013;5.9 months) for placebo, representing a 22% reduction in disease progression (hazard ratio: 0.71; 95% CI: 0.33&#x02013;0.85; <italic>P</italic>&#x0003c;0.001).</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Comparison of PFS and OS for placebo-controlled and <italic>nab</italic>-paclitaxel groups.</title><p>(<bold>A</bold>) PFS and (<bold>B</bold>) OS were estimated by Kaplan&#x02013;Meier curves for patients with advanced NSCLC, in placebo-controlled group and <italic>nab</italic>-paclitaxel group.</p></caption><graphic xlink:href="bsr-37-bsr20170020-g1"/></fig></sec><sec id="sec3-3"><title>Safety</title><p>Grades 3 and 4 AEs were compared between the two groups (<xref ref-type="table" rid="T3">Table 3</xref>). The total grades 3 and 4 AE rates were 6.5 (4/46) for placebo-controlled and 34.8% (16/46) for <italic>nab</italic>-paclitaxel respectively. In both the groups, the highest rate of grade 3 or 4 AEs was diarrhea, accounting for 4.3 (2/46) of total patients in placebo-controlled group and 13.0% (6/46) of total patients in the nab-paclitaxel group. In placebo-controlled group, other grades 3 and 4 AEs were nausea (2.2%, 1/46), fatigue (2.2%, 1/46), thrombocytopaenia (2.2%, 1/46) and leucopenia (4.3%, 2/46). In the <italic>nab</italic>-paclitaxel group, other grades 3 and 4 AEs were fatigue (13.0%, 6/46), infection (10.9%, 5/46), leucopenia (10.9%, 5/46) and rash (8.7%, 4/46).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Grades 3 and 4 AEs of patients with advanced NSCLC</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">AEs</th><th colspan="2" align="center" rowspan="1">Placebo (<italic>n</italic>=46)</th><th colspan="2" align="center" rowspan="1">Nab-paclitaxel (<italic>n</italic>=46)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">34.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Rash</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">8.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Stomatitis</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Pruritus</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Anorexia</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhoea</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.3</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">13.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Paronychia</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatigue</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">13.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Infection</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">10.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Thrombocytopaenia</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">8.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary fibrosis</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Leucopenia</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.3</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">10.9</td></tr></tbody></table></table-wrap></sec></sec><sec id="sec4"><title>Discussions</title><p>In the present study, we performed a randomized placebo-controlled phase II study to investigate the efficacy and safety of <italic>nab</italic>-paclitaxel as a single reagent to treat Chinese patients with advanced NSCLC in second-line chemotherapy. Our study showed that the objective response was significantly improved from 4.3 (2/46) for placebo to 19.6% (9/46) for <italic>nab</italic>-paclitaxel. We also showed that PFS and OS were significantly improved by <italic>nab</italic>-paclitaxel. The PFS was improved from 2.0 (95% CI: 0.9&#x02013;4.3 months) in placebo-controlled group to 4.6 months (95% CI: 3.4&#x02013;6.7 months) for <italic>nab</italic>-paclitaxel group (hazard ratio: 0.62; 95% CI: 0.33&#x02013;0.81; <italic>P</italic>&#x0003c;0.001). The median OS was also improved, from 4.9 months (95% CI: 2.1&#x02013;5.9 months) in placebo-controlled group to 6.3 months (95% CI: 3.9&#x02013;8.2 months) in nab-paclitaxel group (hazard ratio: 0.71; 95% CI: 0.33&#x02013;0.85; <italic>P</italic>&#x0003c;0.001).</p><p>Currently, three chemotherapy reagents, docetaxel, permetrexed and erlotinib have been approved by FDA to be used as second-line chemotherapy reagents for patients with NSCLC. Shepherd et al. [<xref rid="B15" ref-type="bibr">15</xref>] conducted a phase III, randomized, placebo-controlled, double-blind trial to determine whether erlotinib prolonged survival in NSCLC after the failure of first- or second-line chemotherapy. It showed that erlotinib (150 mg q.d.) significantly increased PFS (2.2 months compared with 1.8 months for placebo, <italic>P</italic>&#x0003c;0.001) and OS (6.7 months compared with 4.7 months for placebo, <italic>P</italic>&#x0003c;0.001) in patients with stage IIIB or IV NSCLC who failed first- or second-line treatments. Hanna et al. [<xref rid="B16" ref-type="bibr">16</xref>] compared the efficacy and toxicity of pemetrexed compared with docetaxel in patients with advanced NSCLC having previous chemotherapy in a phase III trial. It showed that pemetrexed and docetaxel had similar efficacy in the median PFS (2.9 months compared with 2.9 months, <italic>P</italic>&#x0003e;0.05) and median survival time (8.3 months compared with 7.9 months, <italic>P</italic>&#x0003e;0.05). Li et al. [<xref rid="B17" ref-type="bibr">17</xref>] investigated the effects of erlotinib and pemetrexed on the median PFS of EGFR wild-type lung adenocarcinoma patients who previously underwent one platinum-based chemotherapy. The results showed that the median PFS was 4.1 months (95% CI: 1.6&#x02013;6.6 months) in the erlotinib group compared with 3.9 months (95% CI: 2.7&#x02013;5.1 months) in the pemetrexed group. Hu and Zhang [<xref rid="B18" ref-type="bibr">18</xref>] reported that the median PFS of patients with advanced NSCLC after first-line platinum-based chemotherapy was 3.5 months (95% CI: 1.9&#x02013;5.8 months) receiving <italic>nab</italic>-paclitaxel 100 mg/m (2) (i.v.) on days 1, 8 and 15 of a 28-day cycle. Liu et al. [<xref rid="B19" ref-type="bibr">19</xref>] compared the median PFS of patients with advanced NSCLC after unsuccessful first-line chemotherapy and the results showed that the <italic>nab</italic>-paclitaxel had better PFS (5.1 months) than pemetrexed (4.6 months). Similarly, our study also showed that the <italic>nab</italic>-paclitaxel had good efficacy in PFS (4.6 months). However, there were several factors in the present study contributing to this result. First, the sample size of the present study was relatively small as compared with the previous trials. A large pool of patients with multiple-centre study would yield more accurate rates on survival. Second, only Chinese patients were enrolled in the present study and the differences of ethnicity probably resulted in the differences of survival between these studies. Third, it was not a multicentre study that caused inevitable and unpredictable errors.</p><p>In the present study, we found that the patients were more likely to experience grade 3/4 AEs in nab-paclitaxel group, than in placebo-controlled group. The total incidence rate of grade 3 or 4 AEs was 34.8% for <italic>nab</italic>-paclitaxel. Shepherd et al. [<xref rid="B15" ref-type="bibr">15</xref>] reported that 26 patients (5%) discontinued treatment due to the severe toxic effects and 19% erlotinib group required dose reductions because of drug-related toxic effects. Among them, most frequent AE was rash (12%) and diarrhoea (5%). Hanna et al. [<xref rid="B16" ref-type="bibr">16</xref>] showed that patients receiving docetaxel were more likely to have grade 3 or 4 neutropaenia (40.2% compared with 5.3%, <italic>P</italic>&#x0003c;.001), febrile neutropaenia (12.7% compared with 1.9%, <italic>P</italic>&#x0003c;.001), neutropaenia with infections (3.3% compared with 0.0%, <italic>P</italic>=0.004), hospitalizations for neutropaenic fever (13.4% compared with 1.5%, <italic>P</italic>&#x0003c;.001), hospitalizations due to other drug-related AEs (10.5% compared with 6.4%, <italic>P</italic>=0.092) compared with patients receiving pemetrexed. Cappuzzo et al. [<xref rid="B20" ref-type="bibr">20</xref>] reported that most common grade 3 AEs of erlotinib treatment were rash (9%) and diarrhoea (2%). Liu et al. [<xref rid="B19" ref-type="bibr">19</xref>] reported that the most occurred grade 3/4 AEs were rash (<italic>n</italic>=4, 7.1%), nausea (<italic>n</italic>=2, 3.6%), paronychia (<italic>n</italic>=2, 3.6%), anorexia (<italic>n</italic>=2, 3.6%) and thrombocytopaenia (<italic>n</italic>=2, 3.6%) in patients with advanced NSCLC receiving pemetrexed treatment. Therefore, in the present study, the toxicity rates were similar with that of erlotinib and docetaxel, however, it seemed to be slightly higher than that of pemetrexed.</p><p>Overall, the promising results from our study showed that <italic>nab</italic>-paclitaxel may be used as a new chemotherapy reagent for second-line treatment for patients with advanced NSCLC.</p></sec></body><back><sec id="sec5" sec-type="funding"><title>Funding</title><p>The authors declare that there are no sources of funding to be acknowledged.</p></sec><sec id="sec6" sec-type="author-contrib"><title>Author contribution</title><p>Wu Yueming: drafting of the manuscript; Feng Jiang: patient recruitment, admission and management; Hu Weiwei: patient management, statistics; Luo Qingquan: assistance wiyh project design</p></sec><sec id="sec7" sec-type="COI-statement"><title>Competing interests</title><p>The authors declare that there are no competing interests associated with the manuscript.</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="G1">AE</term><def><p>adverse event</p></def></def-item><def-item><term id="G2">CI</term><def><p>confidence interval</p></def></def-item><def-item><term id="G3">ECOG</term><def><p>Eastern Cooperative Oncology Group</p></def></def-item><def-item><term id="G4">NSCLC</term><def><p>non-small cell lung cancer</p></def></def-item><def-item><term id="G5">OS</term><def><p>overall survival</p></def></def-item><def-item><term id="G6">PFS</term><def><p>progression-free survival</p></def></def-item><def-item><term id="G7">PS</term><def><p>performance status</p></def></def-item><def-item><term id="G8">RR</term><def><p>response rate</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name>, <name><surname>Zheng</surname><given-names>R.</given-names></name>, <name><surname>Baade</surname><given-names>P.D.</given-names></name>, <name><surname>Zhang</surname><given-names>S.</given-names></name>, <name><surname>Zeng</surname><given-names>H.</given-names></name>, <name><surname>Bray</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2016</year>) <article-title>Cancer statistics in China, 2015</article-title>. <source>CA Cancer J. Clin.</source>
<volume>66</volume>, <fpage>115</fpage>&#x02013;<lpage>132</lpage><pub-id pub-id-type="pmid">26808342</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>L.A.</given-names></name>, <name><surname>Bray</surname><given-names>F.</given-names></name>, <name><surname>Siegel</surname><given-names>R.L.</given-names></name>, <name><surname>Ferlay</surname><given-names>J.</given-names></name>, <name><surname>Lortet-Tieulent</surname><given-names>J.</given-names></name> and <name><surname>Jemal</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>) <article-title>Global cancer statistics, 2012</article-title>. <source>CA Cancer J. Clin.</source>
<volume>65</volume>, <fpage>87</fpage>&#x02013;<lpage>108</lpage><pub-id pub-id-type="pmid">25651787</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name>, <name><surname>DeSantis</surname><given-names>C.</given-names></name>, <name><surname>Virgo</surname><given-names>K.</given-names></name>, <name><surname>Stein</surname><given-names>K.</given-names></name>, <name><surname>Mariotto</surname><given-names>A.</given-names></name>, <name><surname>Smith</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2012</year>) <article-title>Cancer treatment and survivorship statistics, 2012</article-title>. <source>CA Cancer J. Clin.</source>
<volume>62</volume>, <fpage>220</fpage>&#x02013;<lpage>241</lpage><pub-id pub-id-type="pmid">22700443</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>G.R.</given-names></name></person-group> (<year>2014</year>) <article-title>nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update</article-title>. <source>Clin. Lung Cancer</source>
<volume>15</volume>, <fpage>391</fpage>&#x02013;<lpage>397</lpage><pub-id pub-id-type="pmid">25246384</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzoli</surname><given-names>C.G.</given-names></name>, <name><surname>Temin</surname><given-names>S.</given-names></name> and <name><surname>Giaccone</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>) <article-title>2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer</article-title>. <source>J. Oncol. Pract.</source>
<volume>8</volume>, <fpage>63</fpage>&#x02013;<lpage>66</lpage><pub-id pub-id-type="pmid">22548014</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name>, <name><surname>Fillmore</surname><given-names>C.M.</given-names></name>, <name><surname>Hammerman</surname><given-names>P.S.</given-names></name>, <name><surname>Kim</surname><given-names>C.F.</given-names></name> and <name><surname>Wong</surname><given-names>K.K.</given-names></name></person-group> (<year>2014</year>) <article-title>Non-small-cell lung cancers: a heterogeneous set of diseases</article-title>. <source>Nat. Rev. Cancer</source>
<volume>14</volume>, <fpage>535</fpage>&#x02013;<lpage>546</lpage><pub-id pub-id-type="pmid">25056707</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melosky</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>) <article-title>Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer</article-title>. <source>Front. Oncol.</source>
<volume>4</volume>, <fpage>256</fpage><pub-id pub-id-type="pmid">25325013</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reck</surname><given-names>M.</given-names></name>, <name><surname>Popat</surname><given-names>S.</given-names></name>, <name><surname>Reinmuth</surname><given-names>N.</given-names></name>, <name><surname>De Ruysscher</surname><given-names>D.</given-names></name>, <name><surname>Kerr</surname><given-names>K.M.</given-names></name>, <name><surname>Peters</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2014</year>) <article-title>Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann. Oncol.</source>
<volume>25</volume>, <fpage>iii27</fpage>&#x02013;<lpage>iii39</lpage><pub-id pub-id-type="pmid">25115305</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socinski</surname><given-names>M.A.</given-names></name>, <name><surname>Okamoto</surname><given-names>I.</given-names></name>, <name><surname>Hon</surname><given-names>J.K.</given-names></name>, <name><surname>Hirsh</surname><given-names>V.</given-names></name>, <name><surname>Dakhil</surname><given-names>S.R.</given-names></name>, <name><surname>Page</surname><given-names>R.D.</given-names></name><etal/></person-group> (<year>2013</year>) <article-title>Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer</article-title>. <source>Ann. Oncol.</source>
<volume>24</volume>, <fpage>2390</fpage>&#x02013;<lpage>2396</lpage><pub-id pub-id-type="pmid">23842283</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Y.</given-names></name>, <name><surname>Wang</surname><given-names>L.</given-names></name>, <name><surname>Xia</surname><given-names>G.H.</given-names></name> and <name><surname>Shi</surname><given-names>M.Q.</given-names></name></person-group> (<year>2014</year>) <article-title>Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer</article-title>. <source>Asian Pac. J. Cancer Prev.</source>
<volume>15</volume>, <fpage>7453</fpage>&#x02013;<lpage>7457</lpage><pub-id pub-id-type="pmid">25227858</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socinski</surname><given-names>M.A.</given-names></name>, <name><surname>Bondarenko</surname><given-names>I.</given-names></name>, <name><surname>Karaseva</surname><given-names>N.A.</given-names></name>, <name><surname>Makhson</surname><given-names>A.M.</given-names></name>, <name><surname>Vynnychenko</surname><given-names>I.</given-names></name>, <name><surname>Okamoto</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2012</year>) <article-title>Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial</article-title>. <source>J. Clin. Oncol.</source>
<volume>30</volume>, <fpage>2055</fpage>&#x02013;<lpage>2062</lpage><pub-id pub-id-type="pmid">22547591</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosein</surname><given-names>P.J.</given-names></name>, <name><surname>de Lima Lopes</surname><given-names>G.</given-names><suffix>Jr</suffix></name>, <name><surname>Pastorini</surname><given-names>V.H.</given-names></name>, <name><surname>Gomez</surname><given-names>C.</given-names></name>, <name><surname>Macintyre</surname><given-names>J.</given-names></name>, <name><surname>Zayas</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2013</year>) <article-title>A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer</article-title>. <source>Am. J. Clin. Oncol.</source>
<volume>36</volume>, <fpage>151</fpage>&#x02013;<lpage>156</lpage><pub-id pub-id-type="pmid">22307213</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Hoff</surname><given-names>D.D.</given-names></name>, <name><surname>Ervin</surname><given-names>T.</given-names></name>, <name><surname>Arena</surname><given-names>F.P.</given-names></name>, <name><surname>Chiorean</surname><given-names>E.G.</given-names></name>, <name><surname>Infante</surname><given-names>J.</given-names></name>, <name><surname>Moore</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2013</year>) <article-title>Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</article-title>. <source>N. Engl. J. Med.</source>
<volume>369</volume>, <fpage>1691</fpage>&#x02013;<lpage>1703</lpage><pub-id pub-id-type="pmid">24131140</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>Y.</given-names></name>, <name><surname>Nishina</surname><given-names>T.</given-names></name>, <name><surname>Yasui</surname><given-names>H.</given-names></name>, <name><surname>Goto</surname><given-names>M.</given-names></name>, <name><surname>Muro</surname><given-names>K.</given-names></name>, <name><surname>Tsuji</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>) <article-title>Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer</article-title>. <source>Cancer Sci.</source>
<volume>105</volume>, <fpage>812</fpage>&#x02013;<lpage>817</lpage><pub-id pub-id-type="pmid">24716542</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>F.A.</given-names></name>, <name><surname>Rodrigues Pereira</surname><given-names>J.</given-names></name>, <name><surname>Ciuleanu</surname><given-names>T.</given-names></name>, <name><surname>Tan</surname><given-names>E.H.</given-names></name>, <name><surname>Hirsh</surname><given-names>V.</given-names></name>, <name><surname>Thongprasert</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2005</year>) <article-title>Erlotinib in previously treated non-small-cell lung cancer</article-title>. <source>N. Engl. J. Med.</source>
<volume>353</volume>, <fpage>123</fpage>&#x02013;<lpage>132</lpage><pub-id pub-id-type="pmid">16014882</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>N.</given-names></name>, <name><surname>Shepherd</surname><given-names>F.A.</given-names></name>, <name><surname>Fossella</surname><given-names>F.V.</given-names></name>, <name><surname>Pereira</surname><given-names>J.R.</given-names></name>, <name><surname>De Marinis</surname><given-names>F.</given-names></name>, <name><surname>von Pawel</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2004</year>) <article-title>Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy</article-title>. <source>J. Clin. Oncol.</source>
<volume>22</volume>, <fpage>1589</fpage>&#x02013;<lpage>1597</lpage><pub-id pub-id-type="pmid">15117980</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N.</given-names></name>, <name><surname>Ou</surname><given-names>W.</given-names></name>, <name><surname>Yang</surname><given-names>H.</given-names></name>, <name><surname>Liu</surname><given-names>Q.W.</given-names></name>, <name><surname>Zhang</surname><given-names>S.L.</given-names></name>, <name><surname>Wang</surname><given-names>B.X.</given-names></name><etal/></person-group> (<year>2014</year>) <article-title>A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma</article-title>. <source>Cancer</source>
<volume>120</volume>, <fpage>1379</fpage>&#x02013;<lpage>1386</lpage><pub-id pub-id-type="pmid">24481719</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W.</given-names></name> and <name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group> (<year>2015</year>) <article-title>A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer</article-title>. <source>Med. Oncol.</source>
<volume>32</volume>, <fpage>498</fpage><pub-id pub-id-type="pmid">25944796</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name>, <name><surname>Wei</surname><given-names>Z.</given-names></name>, <name><surname>Hu</surname><given-names>Y.</given-names></name>, <name><surname>Gao</surname><given-names>F.</given-names></name>, <name><surname>Hao</surname><given-names>L.</given-names></name>, <name><surname>Fang</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer</article-title>. <source>Med. Oncol.</source>
<volume>32</volume>, <fpage>216</fpage><pub-id pub-id-type="pmid">26168982</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappuzzo</surname><given-names>F.</given-names></name>, <name><surname>Ciuleanu</surname><given-names>T.</given-names></name>, <name><surname>Stelmakh</surname><given-names>L.</given-names></name>, <name><surname>Cicenas</surname><given-names>S.</given-names></name>, <name><surname>Szcz&#x000e9;sna</surname><given-names>A.</given-names></name>, <name><surname>Juh&#x000e1;sz</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2010</year>) <article-title>Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study</article-title>. <source>Lancet Oncol.</source>
<volume>11</volume>, <fpage>521</fpage>&#x02013;<lpage>529</lpage><pub-id pub-id-type="pmid">20493771</pub-id></mixed-citation></ref></ref-list></back></article>